Harvard Bioscience, Inc. filed a Form 8-K on November 10, 2026, disclosing under Item 7.01 (Regulation FD) that the company had attached its current corporate slide presentation, dated November 2026, for distribution to the investment community.

Key Highlights

  • Filing date: November 10, 2026, as reported by Harvard Bioscience, Inc.
  • Disclosure item: Item 7.01, Regulation FD Disclosure, covering a corporate slide presentation.
  • Exhibit filed: Exhibit 99.1, described as the corporate slide presentation of Harvard Bioscience, Inc., dated November 2026.
  • Non-filed status: The filing states the information in Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signatory: The report was signed by Mark Frost, Chief Financial Officer of Harvard Bioscience, Inc.

Harvard Bioscience Discloses Corporate Slide Presentation to Investment Community

Harvard Bioscience, Inc. (NASDAQ:HBIO), headquartered at 84 October Hill Road, Holliston, MA 01746, submitted a Current Report on Form 8-K dated November 10, 2026. The filing was made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company disclosed under Item 7.01 that it "from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business."

The corporate slide presentation, attached as Exhibit 99.1, is described in the filing as dated November 2026. The filing also includes Exhibit 104, identified as a Cover Page Interactive Data File embedded within the Inline XBRL document. No financial statements were included in the filing.

The filing explicitly notes that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing." The report was signed on behalf of the registrant by Chief Financial Officer Mark Frost.

What Was Disclosed

Harvard Bioscience filed an 8-K on November 10, 2026, attaching a corporate slide presentation under Regulation FD. The presentation, Exhibit 99.1, is dated November 2026 and was described as intended for distribution to the investment community at industry and other conferences.